Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/05/2022* -- Results Q2 2022 -- -0.22 --
08/05/2022* 08:30 EST Earnings Call Q2 2022 -- -- --
04/27/2022 -- Results Q1 2022 -- -0.24 --
04/27/2022 08:30 EST Earnings Call Q1 2022 -- -- --
02/23/2022 -- Results Q4 2021 -0.14 -0.15 3.75%
02/23/2022 08:30 EST Earnings Call Q4 2021 -- -- --
11/04/2021 -- Results Q3 2021 -0.08 -0.09 6.79%
11/04/2021 08:30 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 08/05/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 04/27/2022
Beat/Miss Upgrade
Return Since -19.64%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
URL https://www.neogenomics.com
Investor Relations URL https://ir.neogenomics.com/
HQ State/Province Florida
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Aug. 05, 2022 (est.)
Last Earnings Release Apr. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
88.73%
8.89%
3.38%
42.33%
132.0%
84.07%
-36.63%
-75.41%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.21%
--
--
--
--
--
131.4%
-66.78%
-43.74%
--
--
--
--
--
--
-60.64%
-58.33%
--
--
--
--
--
--
--
-63.24%
--
--
--
--
--
--
--
-70.76%
As of May 18, 2022.

Profile

Edit
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
URL https://www.neogenomics.com
Investor Relations URL https://ir.neogenomics.com/
HQ State/Province Florida
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Aug. 05, 2022 (est.)
Last Earnings Release Apr. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PDFDX 267300.0 USD 2.38%
DGASX 421553.0 USD 1.59%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NEO Tweets